Navigation Links
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Date:3/31/2008

d

by our market research resources that there are approximately two

million bone grafting procedures in the United States every year. The

market for orthopedic biomaterials used in these procedures was

estimated to be approximately $4 billion in 2006. In addition, the

fastest growing segment of this market is recombinant protein products

which is expected to grow to $2.9 billion by 2012.

-- We are developing second-generation technetium-based imaging agents to

aid in the diagnosis of PD, Dementia with Lewy Bodies (DLB), and

Attention Deficit Hyperactivity Disorder (ADHD). We have previously

demonstrated in non-human primate studies that our technetium-based

agents are effective in binding the to DAT in sufficient quantity and

with high-selectivity to provide a readable image in the normal brain.

During 2007, we devised a new radiolabeling procedure for our

technetium agents that results in a high purity, high yield product as

a prelude to obtaining definitive images in non-human primates.

Continued Intellectual Property (IP) leadership notably in regenerative

therapeutics.

Alseres' IP portfolio includes issued, allowed or granted patents from the

U.S. and other key countries worldwide. During 2007, the company

submitted 14 new patent applications covering our regenerative

therapeutics, molecular imaging, and neurodegenerative disease assets. We

were granted three new patents covering CETHRIN, four additional patents

covering other regenerative therapies and one patent covering our DAT

blocker platform.

Business & Operational Highlights

Licensed Phase I/IIa Regenerative Therapeutics Program in acute SCI.

In December 2006, Alseres licensed, from BioAxone Therapeutic, Inc. of

Montreal, Canada, development and commercialization rights of CETHRIN, as

<
'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
3. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
4. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
5. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
6. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
9. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
10. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... YORK , Feb. 26, 2015 S&P ... Factual Stock Report coverage on MabVax Therapeutics Holdings ... (MBVX) is a clinical stage biotechnology company focused on ... unmet medical needs in the treatment of cancer. MabVax ... based on the protective immune responses generated by patients ...
(Date:2/26/2015)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today reported 2014 full ... key objectives, and financial guidance.  Synageva,s management team ... p.m. EST to review the financial results and ... today,s call by telephone, please dial (877) 445-4603 ...
(Date:2/26/2015)... Angeles, CA (PRWEB) February 26, 2015 ... an online demonstration to support life extension technologies and ... 8pm UTC, Universal Coordinated Time, on March 21st 2015, ... the world. , Eric Schulke, Founder of MILE, ... must act with urgency. The Movement for Indefinite Life ...
(Date:2/26/2015)... Feb. 26, 2015 BioEnterprise today announced that ... attracted more than $2 billion in growth funding during ... national investors, strategic sources, state – including the Ohio ... the $2 billion has been raised in the past ... the heels of the BioEnterprise Midwest Healthcare Growth ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... intended to support renewed strategic transaction,effort, SOUTH ... Bulletin Board: VXGN), a biopharmaceutical company, today announced,the ... of Directors, and the,resignations of three of its ... Stefano, J.D., a principal with the law firm ...
... Health Agency,s Community Health Surveillance System Detects ... ... the course of two hours,on a recent Friday, 20 people arrived, ... Each separately complained of various,gastrointestinal symptoms, including nausea and diarrhea., ...
... Corporation announced today the,commercial release of its Extended ... This technology breaks through classical depth of field,limitations ... of the ImageStream system and enabling new applications,including ... EDF option can be installed at time of ...
Cached Biology Technology:VaxGen Restructures Board of Directors 2E. coli Outbreak in New Jersey? 2E. coli Outbreak in New Jersey? 3Amnis Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System 2
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... team has discovered an influenza detector gene that could ... Katharine Magor, a U of A associate professor ... ducks to live, unharmed, as the host of influenza. ... geneI, or RIG-I, enables a duck,s immune system to ...
... Md. -- Amphibiansfrogs, toads, salamanders, and newtsare disappearing worldwide, ... to be stable. This region is home to the ... 70 species reside here), and scientists want to understand ... In research published in the March 29, 2010 issue ...
... the UK and USA announce plans to promote scientific ... The Biotechnology and Biological Sciences Research Council (BBSRC) ... to hold an intensive week long facilitated workshop ... to bring together leading researchers across all disciplines to ...
Cached Biology News:Young salamanders' movement over land helps stabilize populations 2Young salamanders' movement over land helps stabilize populations 3BBSRC and NSF join together to promote new ideas to enhance photosynthesis 2
...
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... Recombinant Ribonuclease Inhibitor is a ... ribonucleases such as RNase A. ... Recombinant Ribonuclease Inhibitor is an ... weight ~52 kDa. RNaseOUT inhibits ...
... inhibitor) is a 50 kDa ... RNase activity. It does not ... , Inhibits RNase activity, ... , Lacks DNA endonuclease ...
Biology Products: